Cargando…
SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer
INTRODUCTION: Dysregulated receptor tyrosine kinase (RTK) signaling is a common occurrence in basal-like and triple-negative breast cancer (BTBC). As a result, RTK-targeting therapies have been initiated but proved difficult, mainly owing to the multiplicity of dysregulated RTKs. Hence, targeting ma...
Autores principales: | Matalkah, Fatimah, Martin, Elisha, Zhao, Hua, Agazie, Yehenew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700603/ https://www.ncbi.nlm.nih.gov/pubmed/26728598 http://dx.doi.org/10.1186/s13058-015-0659-z |
Ejemplares similares
-
SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer
por: Martin, Elisha, et al.
Publicado: (2021) -
Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment
por: Zhao, Hua, et al.
Publicado: (2015) -
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis
por: Zhao, Hua, et al.
Publicado: (2018) -
Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine
Phosphatase SHP2 with Anti-Breast Cancer Cell Effects
por: Hartman, Zachary, et al.
Publicado: (2020) -
Targeting
SHP2 with an Active Site Inhibitor Blocks
Signaling and Breast Cancer Cell Phenotypes
por: Lade, Dhanaji M., et al.
Publicado: (2023)